Inpatient mortality up with exposure to high capacity utilization
Jan 13, 2023
A 2% increase was seen in the odds of 14-day in-hospital mortality for each additional day of exposure to high-capacity utilization.
Two disease processes contribute to age-related macular degeneration
Jan 13, 2023
Lesions from soft drusen/pigment epithelial detachments have lower mean quantitative autofluorescence, whereas those from subretinal drusenoid deposits have higher.
FDA approves new two-drug combo medicine for asthma
Jan 12, 2023
The medication is the first approved in the United States to contain an inhaled corticosteroid as a reliever rather than as a controller of asthma symptoms.
Older knee replacement implants as good as newer models
Jan 12, 2023
No significant difference was seen in the six-month Oxford Knee Score for the newer Journey II BCS versus the older Genesis II.
Salt restriction does not lower blood pressure variability
Jan 12, 2023
The findings show no difference between a seven-day low- or high-salt diet.
Staffing stability is marker of better quality of nursing homes
Jan 10, 2023
A higher percentage of below-average staffing days was linked to worse quality for licensed practical nurses.
Community gardening improves well-being for adults
Jan 09, 2023
Improvement was seen in fiber intake and moderate-to-vigorous physical activity; a reduction was seen in perceived stress and anxiety.
Social work staffing may increase access, use of palliative care
Jan 05, 2023
An intervention to increase social work staffing on primary care teams serving rural veterans was tied to an increased use of palliative care following hospitalization.
Women with employer insurance more likely to report unaffordability of care
Dec 30, 2022
“[R]ising healthcare costs, growth in high-deductible plans and increased out-of-pocket healthcare expenditures may have contributed to increased unaffordability in recent years,” the authors...
Congressional report slams FDA, drugmaker over approval of Alzheimer’s drug Aduhelm
Dec 29, 2022
The controversy over aducanumab (Aduhelm) stretches back to its June 2021 approval by the US Food and Drug Administration.